Nathan O. Siemers

3.5k citations

29 papers · 1.8k indexed · 2 hit papers · h-index 19

Oncology top 5%
Immunology top 5%
Molecular Biology
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 10%

Co-authors: Scott D. Chasalow Rui‐Ru Ji David M. Berman Lisu Wang John Cogswell Omid Hamid Vafa Shahabi Jeffrey R. Jackson
Topics: Cancer Immunotherapy and Biomarkers (9 papers)Gene expression and cancer classification (5 papers)Immune Cell Function and Interaction (4 papers)
Cited by: Immunology Oncology Cancer Research
Journals: Cell Bioinformatics PLoS ONE
Partner nations: United States Germany United Kingdom

In The Last Decade

Nathan O. Siemers

28 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An immune-active tumor microenvironment favors clinical response to ipilimumab

2011 593 citations Rui‐Ru Ji, Scott D. Chasalow et al. Cancer Immunology Immunotherapy profile →
Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment

2021 236 citations Xianwen Ren, Lei Zhang et al. Annual Review of Immunology profile →

Peers

Countries citing papers authored by Nathan O. Siemers

Since Specialization

Citations

This map shows the geographic impact of Nathan O. Siemers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan O. Siemers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan O. Siemers more than expected).

Fields of papers citing papers by Nathan O. Siemers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan O. Siemers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan O. Siemers. The network helps show where Nathan O. Siemers may publish in the future.

Co-authorship network of co-authors of Nathan O. Siemers

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan O. Siemers. A scholar is included among the top collaborators of Nathan O. Siemers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan O. Siemers. Nathan O. Siemers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors 2024 ·Journal for ImmunoTherapy of Cancer ·Matthew H. Taylor,Aung Naing,John D. Powderly,Paul Woodard,(unknown),Wen Lin,(unknown),Nathan O. Siemers,Hong Xiang,(unknown),Kyu Hong,(unknown),Tao Huang,Ying Zhu,Xuebin Liao,Xiao Min Schebye,Manish Patel	4
2	Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment 2023 ·Scientific Reports ·Péter M. Szabó,Amir Vajdi,Namit Kumar,Michael Tolstorukov,Benjamin J. Chen,Robin Edwards,Keith L. Ligon,Scott D. Chasalow,Kin-Hoe Chow,Aniket Shetty,Mohan Bolisetty,James L. Holloway,Ryan Golhar,Brian Kidd,Philip A. Hull,(unknown),(unknown),Nathan O. Siemers,Saurabh Saha	36
3	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer 2021 ·Clinical Cancer Research ·Ming Lei,Nathan O. Siemers,Dimple Pandya,Han Chang,Teresa Sánchez,Christopher Harbison,Péter M. Szabó,Yelena Y. Janjigian,Patrick A. Ott,Padmanee Sharma,Johanna C. Bendell,T.R. Jeffry Evans,Filippo de Braud,Ian Chau,Zachary Boyd	57
4	Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models 2021 ·Cancer Research ·(unknown),Bryan McDonald,(unknown),Nathan O. Siemers,(unknown),Mark Selby,Tim W. Sproul,Alan J. Korman,(unknown),(unknown),Sharmila Sambanthamoorthy,Kai Lǚ,(unknown),(unknown),Renu Jain,Ruth Y. Lan	76
5	Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironmentbreakdown → 2021 ·Annual Review of Immunology ·Xianwen Ren,Lei Zhang,Yuanyuan Zhang,Ziyi Li,Nathan O. Siemers,Zemin Zhang	236
6	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function 2019 ·Cancer Immunology Research ·Deepak Mittal,Ailin Lepletier,Jason Madore,Amelia Roman Aguilera,Kimberley Stannard,Stephen J. Blake,Vicki Whitehall,Cheng Liu,Mark Bettington,Kazuyoshi Takeda,Georgina V. Long,Richard A. Scolyer,Ruth Y. Lan,Nathan O. Siemers,Alan J. Korman,Michele W.L. Teng,Robert J. Johnston,William C. Dougall,Mark J. Smyth	90
7	Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC) 2019 ·Cancer Research ·Ming Lei,Nathan O. Siemers,Dimple Pandya,Han Chang,Teresa Sánchez,Cécile Dorange,Christopher Harbison,Péter M. Szabó,Yelena Y. Janjigian,Patrick A. Ott,Padmanee Sharma,Johanna C. Bendell,Jonathan J. Evans,Filippo de Braud,Ian Chau,Zachary Boyd	12
8	Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors 2017 ·PLoS ONE ·Nathan O. Siemers,James L. Holloway,Chang Han,Scott D. Chasalow,Petra Ross‐Macdonald,Charles F. Voliva,Joseph D. Szustakowski	162
9	Gene Expression Analyses of Mouse Aortic Endothelium in Response to Atherogenic Stimuli 2013 ·Arteriosclerosis Thrombosis and Vascular Biology ·Ayça Erbilgin,Nathan O. Siemers,Paul S. Kayne,Wen-Pin Yang,Judith A. Berliner,Aldons J. Lusis	27
10	Unraveling Inflammatory Responses using Systems Genetics and Gene-Environment Interactions in Macrophages 2012 ·Cell ·Luz D. Orozco,Brian J. Bennett,Charles R. Farber,Anatole Ghazalpour,Calvin Pan,Nam Che,Ping-Zi Wen,Hong Qi,(unknown),Nathan O. Siemers,Isaac Neuhaus,Roumyana Yordanova,Peter S. Gargalovic,Matteo Pellegrini,Todd G. Kirchgessner,Aldons J. Lusis	98
11	Exome Sequencing Reveals Comprehensive Genomic Alterations across Eight Cancer Cell Lines 2011 ·PLoS ONE ·Han Chang,Donald Jackson,Paul S. Kayne,Petra Ross‐Macdonald,Rolf-Peter Ryseck,Nathan O. Siemers	19
12	An immune-active tumor microenvironment favors clinical response to ipilimumabbreakdown → 2011 ·Cancer Immunology Immunotherapy ·Rui‐Ru Ji,Scott D. Chasalow,Lisu Wang,Omid Hamid,Henrik Schmidt,John Cogswell,Suresh Alaparthy,David M. Berman,Maria Jure–Kunkel,Nathan O. Siemers,Jeffrey R. Jackson,Vafa Shahabi	593
13	Transcriptional Profiling of the Dose Response: A More Powerful Approach for Characterizing Drug Activities 2009 ·PLoS Computational Biology ·Rui‐Ru Ji,Heshani de Silva,(unknown),Robert E. Bruccoleri,Jian Cao,Aiqing He,Wenjun Huang,Paul S. Kayne,Isaac Neuhaus,Karl‐Heinz Ott,Becky Penhallow,Mark I. Cockett,Michael Neubauer,Nathan O. Siemers,Petra Ross‐Macdonald	22
14	Gene Set Enrichment Analysis 2009 ·Methods in molecular biology ·Charles Tilford,Nathan O. Siemers	68
15	HBEGF, SRA1, and IK: Three cosegregating genes as determinants of cardiomyopathy 2008 ·Genome Research ·Frauke Friedrichs,Christian Zugck,Gerd-Jörg Rauch,Boris Ivandic,Dieter Weichenhan,Margit Müller-Bardorff,Benjamin Meder,Nour Eddine El Mokhtari,Vera Regitz‐Zagrosek,Roland Hetzer,Arne Schäfer,Stefan Schreiber,Jian Chen,Isaac Neuhaus,Rui‐Ru Ji,Nathan O. Siemers,Norbert Frey,Wolfgang Rottbauer,Hugo A. Katus,Monika Stoll	74
16	Nearest Neighbor Networks: clustering expression data based on gene neighborhoods 2007 ·BMC Bioinformatics ·Curtis Huttenhower,Avi I. Flamholz,J. Landis,(unknown),Chad L. Myers,Kellen Olszewski,Matthew Hibbs,Nathan O. Siemers,Olga G. Troyanskaya,Hilary A. Coller	52
17	Structural and functional characterization of CFE88: Evidence that a conserved and essential bacterial protein is a methyltransferase 2005 ·Protein Science ·Keith L. Constantine,Stanley R. Krystek,Matthew D. Healy,Michael L. Doyle,Nathan O. Siemers,Jane A. Thanassi,Ning Yan,Dianlin Xie,Valentina Goldfarb,Joseph Yanchunas,Tao Li,Brian Dougherty,Bennett T. Farmer	4
18	Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-β-Lactamase fusion protein 2003 ·Bioorganic & Medicinal Chemistry Letters ·Vivekananda M. Vrudhula,David E. Kerr,Nathan O. Siemers,Gene M. Dubowchik,Peter D. Senter	24
19	Mathematical and experimental analysis of localization of anti-tumour antibody–enzyme conjugates 1999 ·British Journal of Cancer ·Trachette L. Jackson,Sharon R. Lubkin,Nathan O. Siemers,David E. Kerr,Peter D. Senter,J. D. Murray	12
20	Periplanone total synthesis via intramolecular pinacol coupling 1994 ·Tetrahedron Letters ·John E. McMurry,Nathan O. Siemers	22

About Nathan O. Siemers

Nathan O. Siemers is a scholar working on Oncology, Immunology and Biotechnology, having authored 29 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Gene expression and cancer classification (5 papers) and Immune Cell Function and Interaction (4 papers). The work is most often cited by research in Immunology (751 citations), Oncology (941 citations) and Cancer Research (272 citations). Nathan O. Siemers has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Scott D. Chasalow, Rui‐Ru Ji, David M. Berman, Lisu Wang, John Cogswell, Omid Hamid, Vafa Shahabi, Jeffrey R. Jackson, Maria Jure–Kunkel and Suresh Alaparthy. Their work appears in journals such as Cell, Bioinformatics and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact